TABLE 1.
Strain and treatmenta | Level (μM) of: |
||||||||
---|---|---|---|---|---|---|---|---|---|
RF | FAD | FMN | RoF | RoFAD | RoFMN | AF | AFAD | AFMN | |
wt | |||||||||
DMSO | 0 | 60 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
RF | 0 | 84 | 17 | 0 | 0 | 0 | 0 | 0 | 0 |
RoF | 0 | 11 | 0 | 4 | 63 | 7 | 0 | 0 | 0 |
AF | 0 | 18 | 0 | 0 | 0 | 0 | 35 | 64 | 26 |
M1 | |||||||||
DMSO | 0 | 74 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
RF | 14 | 140 | 24 | 0 | 0 | 0 | 0 | 0 | 0 |
RoF | 0 | 24 | 0 | 20 | 113 | 16 | 0 | 0 | 0 |
AF | 0 | 29 | 0 | 0 | 0 | 0 | 65 | 88 | 28 |
Strains (wt, wild type; M1, deregulated Rli96-defective strain) were treated with 100 μM riboflavin (RF), 100 μM roseoflavin (RoF), or 100 μM 8-demethyl-8-aminoriboflavin (AF).